{"nctId":"NCT03040726","briefTitle":"Netupitant and Palonosetron Hydrochloride in Preventing Chronic Nausea and Vomiting in Patients With Cancer","startDateStruct":{"date":"2017-05-03","type":"ACTUAL"},"conditions":["Malignant Neoplasm","Nausea","Vomiting"],"count":53,"armGroups":[{"label":"Group I (netupitant, palonosetron hydrochloride)","type":"EXPERIMENTAL","interventionNames":["Drug: Netupitant","Drug: Palonosetron","Drug: Palonosetron Hydrochloride","Other: Questionnaire Administration"]},{"label":"Group II (placebo)","type":"PLACEBO_COMPARATOR","interventionNames":["Other: Placebo","Other: Questionnaire Administration"]}],"interventions":[{"name":"Netupitant","otherNames":["CID6451149","D05152","RO 67-3189/000"]},{"name":"Palonosetron","otherNames":[]},{"name":"Palonosetron Hydrochloride","otherNames":["Aloxi","RS 25259-197"]},{"name":"Placebo","otherNames":["placebo therapy","PLCB","sham therapy"]},{"name":"Questionnaire Administration","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Diagnosis of cancer\n* Chronic nausea over the past 4 weeks\n* Average nausea numeric rating scale \\>= 4/10 over the past 5 days at screening\n* Outpatient at MD Anderson Cancer Center\n* Karnofsky performance status \\>= 50%\n* Age 18 or older\n* Able to complete study assessments, including keeping a daily diary\n\nExclusion Criteria:\n\n* Delirium (i.e. Memorial Delirium Rating Scale \\> 13)\n* Clinical evidence of bowel obstruction at the time of study enrollment\n* Expected to use other 5HT3 antagonists or NK1 antagonists for prophylaxis during the study\n* Continuation of over-the-counter therapies for nausea and/or vomiting during the study\n* On cytotoxic chemotherapy in the high/moderate/low emetogenic risk categories or oral antineoplastic agents in the high or moderate emetogenic risk categories according to the latest National Comprehensive Cancer Network (NCCN) guideline within 2 weeks of study enrollment\n* On scheduled potent CYP3A4 inducers at the time of study enrollment (avasimibe, carbamazepine, phenytoin, rifampin, efavirenz, nevirapine, barbiturates, systemic glucocorticoids, modafinil, oxcarbazine, phenobarbital, pioglitazone, rifabutin, St. John's wort, troglitazone)\n* On scheduled CYP3A4 substrates with narrow safety range at the time of study enrollment (alfentanil, cyclosporine, dihydroergotamine, ergotamine, pimozide, quinidine, sirolimus, tacrolimus)\n* On scheduled strong or moderate CYP3A4 inhibitors (boceprevir, clarithromycin, conivaptan, indinavir, itraconazole, ketoconazole, lopinavir/ritonavir, mibefradil, nefazodone, nelfinavir, posaconazole, ritonavir, saquinavir, telaprevir, telithromycin, voriconazole; amprenavir, aprepitant, atazanavir, ciprofloxacin, darunavir/ritonavir, diltiazem, erythromycin, fluconazole, fosamprenavir, grapefruit juice, imatinib, verapamil) within one week of study enrollment\n* Unwilling to provide informed consent\n* Severe renal impairment (calculated creatinine clearance =\\< 29 cc/min)\n\n  * Calculated creatinine clearance can be done within 14 days of study enrollment\n* Severe liver impairment (Child-Pugh score \\> 9)\n\n  * Total (T.) bilirubin, albumin, prothrombin time, and serum creatinine tests can be done within 14 days of study enrollment (only if not performed in the last 14 days)\n* Females who are pregnant, lactating, or intend to become pregnant during the participation of the study; childbearing age women who are not on birth control; positive pregnancy test for women of childbearing potential, as defined by intact uterus and ovaries, and no history of menses within the last 12 months; pregnancy test to be performed on the day of enrollment; in cases of women with elevated beta-human chorionic gonadotropin (b-HCG), these candidates will be eligible to participate so long as the level of b-HCG is not consistent with pregnancy and the non-pregnant status is confirmed by a gynecologic examination","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change in Nausea Numerical Rating Scale (NRS) Between Day 5 and Day 15","description":"Average intensity of nausea over the past 24 hours was assessed daily using a validated numeric rating scale from 0 to 10, where 0= none and 10= worse possible nausea. The total score ranged from 0-10. We measured the within-group change in nausea intensity from day 5 to day 15. Wilcoxon rank sum test was used for analysis.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.0","spread":null},{"groupId":"OG001","value":"-2.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Functional Living Index Emesis (FLIE): Nausea Sub-score","description":"FLIE is a questionnaire validated to assess the impact of chemotherapy induced nausea and vomiting on patient's function and quality of life over the past 5 days. It consists of 18 items, with 9 items on nausea and 9 items on vomiting. Each question was rated using a Numerical Rating Scale (NRS) from 1 to 7. The total Nausea sub-score ranges from 9 to 63, where a higher score indicates higher quality of life. We measured the change of nausea sub-score between baseline 5 to day 15. Wilcoxon rank sum test was used for analysis.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-16.6","spread":null},{"groupId":"OG001","value":"-18","spread":null}]}]}]},{"type":"SECONDARY","title":"Functional Living Index Emesis (FLIE): Vomiting Sub-score","description":"FLIE is a questionnaire validated to assess the impact of chemotherapy induced nausea and vomiting on patient's function and quality of life over the past 5 days. It consists of 18 items, with 9 items on nausea and 9 items on vomiting. Each question was rated using a Numerical Rating Scale (NRS) from 1 to 7. The total Vomiting sub-score ranges from 9 to 63, where a higher score indicates higher quality of life. We measured the change of vomiting sub-score from baseline to day 15.Wilcoxon rank sum test was used for analysis.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-12.5","spread":null},{"groupId":"OG001","value":"-9.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Index of Nausea, Vomiting and Retching: Total Experience Score","description":"Index of Nausea, Vomiting, and Retching, which consists of 8 items asking about the patient's experience regarding nausea and vomiting over the past 12 hours. Each item included a 5-point Likert scale (0-4 points) with descriptive words. Total experience score ranged from 0-32 with higher score indicates more nausea/vomiting. We measured the change in score between day 5 and day 15. Wilcoxon rank sum test was used for analysis.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.3","spread":null},{"groupId":"OG001","value":"-2.5","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":1,"n":30},"commonTop":["Headache","Back pain","Constipation","Edema legs","Fatigue"]}}}